<DOC>
	<DOC>NCT01693042</DOC>
	<brief_summary>Single or repeated application of autologous bone marrow-derived stem cells to treat chronic post-infarction heart failure</brief_summary>
	<brief_title>Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure</brief_title>
	<detailed_description>Improve mortality and morbidity in patients with symptomatic chronic post-infarction heart failure under full dose conventional medical and device treatment including resynchronization therapy, by single versus repeated intracoronary infusion of autologous bone marrow-derived mononuclear cells.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<criteria>Previous myocardial infarction at least 3 months ago, open infarct vessel or bypass Left ventricular ejection fraction (LVEF) ≤ 45% on echocardiography Stable chronic heart failure NYHA class II to III under constant (4 weeks) evidencebased optimal medical treatment age 18 80 years written informed consent women of childbearing age: negative pregnancy test; effective contraception for the first 8 months in the trial Nonischemic cardiomyopathy Necessity for revascularization in other vessel than the infarct vessel at the time of study therapy Hemodynamic relevant severe valvular disease with indication for operative / interventional revision Heart failure with preserved ejection fraction (diastolic heart failure), LVEF &gt; 45% Unstable Angina Severe peripheral artery occlusive disease (≥ Fontaine stadium III) Active infection (Creactive protein &gt; 10 mg/dl), chronic active hepatitis; any chronic inflammatory disease, HIV infection Neoplastic disease without documented remission in the last 5 years Stroke ≤ 3 months Impaired renal function (Serum creatinine &gt; 2,5 mg/dl) at the time of study inclusion Relevant liver disease (GOT &gt; 2x upper normal limit, spontaneous INR &gt; 1,5). Diseases of hematopoetic system, anemia (Hemoglobin &lt; 8.5 mg/dl), thrombocytopenia &lt; 100.000/µl) Splenomegaly Allergy or intolerance of clopidogrel, prasugrel, ticagrelor, heparin, bivalirudin History of bleeding disorder gastrointestinal bleeding ≤ 3 months major surgery or trauma ≤ 3 months Uncontrolled hypertension Pregnancy, lactation period mental retardation previous cardiac cell therapy within last 12 months Participation in another clinical trial ≤ 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>heart failure</keyword>
	<keyword>old myocardial infarction</keyword>
	<keyword>bone marrow-derived mononuclear cells</keyword>
	<keyword>chronic</keyword>
	<keyword>ischemic</keyword>
</DOC>